-
Significantly prolong survival, first-line treatment of esophageal cancer has made an important breakthrough in the past 30 years
Time of Update: 2021-04-21
The press release pointed out that this is the first anti-PD-1 immune combination therapy approved by the FDA for the first-line treatment of this patient group, and represents a major breakthrough in the first-line treatment of esophageal cancer in the past 30 years.
-
Significantly prolongs the lives of prostate cancer patients, Novartis targeted radiotherapy reaches the phase 3 clinical endpoint
Time of Update: 2021-04-21
▎Editor of WuXi AppTec's content team On March 23, Novartis announced that its potential "first-in-class" targeted radioligand therapy (RLT) 177Lu-PSMA-617 is in the treatment of stage 3 of patients with advanced prostate cancer.
Retrieved March 23, 2021, from novartis-announces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer[2] Novartis Oncology Pipeline Update.
-
Nat Cancer: Research reveals evidence of immune response in cancer survivors
Time of Update: 2021-04-20
1038/s43018-021-00180-1 Turk said: "We have found that T cells can persist in the skin and blood for many years, and we understand this long-lasting immune response in melanoma patients.
-
PNAS analysis! Develop a new type of cancer immunotherapy that can target common genetic mutations!
Time of Update: 2021-04-20
PNAS scientists from Johns Hopkins University School of Medicine and other institutions have developed a new type of cancer immunotherapy prototype through research, which may be able to engineer T cells to target all common genetic mutations in cancer ( genetic alteration); this new method can stimulate the body's immune response to resist cells that lack a copy of a gene, that is, cells with loss of heterozygosity (LOH).
-
Hypoxia thinking after three months of squatting
Time of Update: 2021-04-20
It is very necessary to study the molecular markers related to hypoxia in breast cancer.
Hypoxia-related DEG prognostic markers and risk characteristics construction Figure 4.
Identification of hypoxia-related differential expression candidate miRNAs and enrichment analysis Figure 5.
Identification of hypoxia Oxygen-related differential expression candidate miRNA 6.
-
New natural enemy of tumor? New antigen vaccine clinical trials are underway
Time of Update: 2021-04-20
Ott and his colleague Eryn Blass from the Dana Farber Cancer Institute in Boston, USA published an article entitled "Advances in the development of personalized neoantigen-based therapeutic" in Nature Reviews-Clinical Oncology.
Personalized neoantigen-based vaccination has the potential to induce long-lasting tumor-specific memory T cell populations.
-
Heavy | Binhui Bio-Clinical Cooperation Agency Announces Phase I/II Clinical Data of Oncolytic Herpes Simplex Virus Type II OH2 Injection
Time of Update: 2021-04-18
This multicenter phase I/II clinical trial included patients with advanced solid tumors who had failed standard therapies and received increasing doses (106, 107, and 108CCID50/mL) of intratumoral single-dose OH2 injection or combined fixed-dose HX008 treatment.
-
Professor Han Baohui: Atelizumab is expected to become a new choice for the first-line treatment of advanced non-small cell lung cancer
Time of Update: 2021-04-18
S. Food and Drug Administration (FDA) with the success of the IMpower110 study Atilizumab is the first-line treatment for patients with metastatic NSCLC with high PD-L1 expression (TC≥50% or IC≥10%) [1].
-
The first phase III clinical study of immune neoadjuvant CheckMate -816 results released: Nivolumab combined with chemotherapy can significantly improve the pCR of lung cancer patients
Time of Update: 2021-04-18
The results showed that compared with chemotherapy alone, patients with stage Ib to IIIa resectable non-small cell lung cancer who received 3 cycles of Odivo combined chemotherapy treatment before surgery can significantly improve tumor pathological complete remission (pCR) and achieve major Study endpoint.
-
Nearly a quarter of lung cancer patients are cancer-free after surgery!
Time of Update: 2021-04-18
The results of the CheckMate 816 randomized trial show that in patients with operable NSCLC, neoadjuvant chemotherapy combined with nivolumab can significantly increase the pathological complete remission rate to 24.
-
Professor Liu Jian: Re-discussion on several hot issues of endocrine therapy for breast cancer | 2021 CSCO BC
Time of Update: 2021-04-18
Table 2 Efficacy and safety differences of first-line targeted endocrine therapy In the PALOMA-2 study, patients were randomly assigned to the pipercillil + letrozole group and the placebo + letrozole group at 2:1, and the study reached the primary endpoint.
-
Express | Blockbuster PD-1 inhibitors in the treatment of early stage lung cancer reach the phase 3 clinical endpoint, which is expected to delay cancer recurrence
Time of Update: 2021-04-18
▎The content team editor of WuXi AppTec recently, Bristol-Myers Squibb (BMS) announced that its blockbuster PD-1 inhibitor Odivo (Navulimab) is combined with chemotherapy to treat patients with early-stage non-small cell lung cancer Positive results at the time.
-
"Self-delivery" RNAi therapy targeting PD-1 has powerful tumor control and tumor microenvironment regulation capabilities | Yimai Meng broke the news
Time of Update: 2021-04-18
Ionis' antisense drug enters clinical phase 3MedMeng broke the news on April 12, 2021/eMedClub News/--Phio Pharmaceuticals (Nasdaq: PHIO) recently announced at the 2021 American Association for Cancer Research (AACR) annual meeting In poster format, the latest research data of the product mPH-762 developed based on its proprietary "Self-delivering" RNAi platform INTASYL™, titled "Intratumoral injection of INTASYL™ targeting PD-1 self-delivered RNAi drugs , Provides in vivo tumor control and tumor microenvironment regulation comparable to anti-PD-1 antibody system therapy.
-
Millions of viruses have been injected into the brain, and the survival period of children with fatal tumors has more than doubled!
Time of Update: 2021-04-18
Image source: 123RF In this trial, 12 patients with high-grade glioma aged 7-18 years received G207 treatment.
The research team also observed that the presence of HSV-1 antibodies in the body before treatment may affect the survival benefits of patients.
-
Cervical cancer welcomes new targeted drugs; "unlimited cancer species" RET inhibitors have "strong efficacy"|Tumor News
Time of Update: 2021-04-18
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the document, you can add
-
The first show of Guangdong Congress (Part 1): True and false CR after ALK-positive lung adenocarcinoma targeted therapy
Time of Update: 2021-04-18
▷Zhong Wenzhao (Chief physician of the Department of Pulmonary Surgery, Guangdong Provincial People's Hospital): This patient is a stage IV ALK-positive lung adenocarcinoma, and achieved clinical CR after treatment with aletinib; the current controversial issue is whether to take further local treatment.
-
Professor Tao Sun: Real-world studies confirm that Chidamide is safe and effective, and early treatment benefits are more significant | 2021 CSCO BC
Time of Update: 2021-04-18
Due to the above results, the combination of chidamide and exemestane in the treatment of advanced HR+ The phase III clinical trial ACE for breast cancer came into being.
-
Professor Qiang Liu: Immunotherapy brings more hope to breast cancer | 2021 CSCO BC
Time of Update: 2021-04-18
In the early study KEYNOTE-086, the results showed that PD-1/PD-L1 monotherapy has a certain effect on metastatic triple-negative breast cancer (mTNBC), but the tumor The remission rate is only 5-26%; the KEYNOTE-119 study compared the efficacy of pembrolizumab vs.
-
Do high-risk PH-ALL patients with negative MRD still need to undergo transplantation?
Time of Update: 2021-04-18
A prospective study evaluated the effect of allo-HSCT on the treatment outcome of PH-ALL patients based on the MRD levels of PH-ALL patients after induction therapy and consolidation therapy.
-
Tumor immune ADC
Time of Update: 2021-04-18
Immunesensor's ADC technology is to couple STING agonists to antibodies.
At this AACR meeting, another biotechnology company Tallac also introduced its new ADC technology TRAAC.
Mersana also reported on the progress of the STING agonist conjugated antibody XMT-2056 at the AACR meeting.
